Economic evaluation for hepatitis C

Table of Contents

• Economic evaluation for hepatitis C

• Structure of talk

• What is economic evaluation?

• Methods of economic evaluation

• Issues in evaluating treatment for HCV

• Markov Model for Hepatitis C

• Evaluating cost-effectiveness for mild HCV

• Literature Based Transition Probabilities

• Results: Overview

• Average Projected Outcomes

• Projected Average Total Costs (£) of Different Stages

• Incremental Cost-effectiveness Ratio (ICER)

• Testing Data Uncertainty using sensitivity analysis

• Sensitivity Analysis: model duration on Cost Per QALY (£)

• Is interferon and ribavarin for mild HCV relatively cost-effective?

• Methodological Issues

• Conclusions

Jenny Roberts, Richard Grieve -Collaborative centre for the economics of infectious diseases-London School of Hygiene and Tropical Medicine